PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29187872-0	2017	Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients.	Sunitinib	41-50	annexin A1	Homo sapiens	8-13	
29187872-4	2017	Our aim with the current study was to assess annexin A1 (ANXA1), which stimulates angiogenesis, as a predictive marker for sunitinib therapy in mRCC patients.	Sunitinib	123-132	annexin A1	Homo sapiens	45-55	
29187872-4	2017	Our aim with the current study was to assess annexin A1 (ANXA1), which stimulates angiogenesis, as a predictive marker for sunitinib therapy in mRCC patients.	Sunitinib	123-132	annexin A1	Homo sapiens	57-62	
29187872-13	2017	Conclusions: Our results indicate that cytoplasmic expression of ANXA1 is a negative predictive marker for sunitinib therapy in mRCC patients.	Sunitinib	107-116	annexin A1	Homo sapiens	65-70